Literature DB >> 11536271

Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement.

P A Benn1, A Gainey, C J Ingardia, J F Rodis, J F Egan.   

Abstract

Second trimester maternal serum alpha-fetoprotein (MS-AFP), human chorionic gonadotrophin (hCG), unconjugated estiol (uE3), and inhibin-A (INH-A) levels were evaluated in pregnancies complicated by triploidy. In addition to seven new triploid pregnancies, the results for 67 published cases were reviewed. All cases appear to fall into two major groups. First, those identifiable as screen-positive for both Down syndrome and an open neural tube defect (ONTD) with elevated MS-AFP, grossly elevated hCG, low/normal uE3, and probably elevated INH-A. Pregnancies in the second group are identifiable as screen-positive for trisomy 18 with low/normal MS-AFP, and very low hCG, uE3 and INH-A. Triploid pregnancies with high maternal serum hCG nearly always show a placenta with partial mole (25/27 or 93%), a high frequency of ONTDs or ventral wall defects (VWDs) (8/28 or 29%) and have either an XXX or XXY karyotype (observed ratio 6:10, respectively). Low hCG is infrequently associated with a molar placenta (1/11 or 9%), does not appear to be associated with ONTDs or VWDs (0/29 or 0%), and shows an excess of XXX over XXY karyotypes (observed ratio 17:2). There were 16 cases with either a molar placenta, an ONTD or a VWD that received the MS-AFP and hCG tests. All 16 were screen-positive for an ONTD (MS-AFP> or =2 multiples of the median). In addition, all 31 cases that received MS-AFP, hCG, uE3 (and where available INH-A) were screen-positive for either Down syndrome or trisomy 18. The findings are discussed in the context of expected differences between digynic and diandric triploidy. It is suggested that the sex chromosome complement in triploidy is an important factor in determining risk for partial mole development and in utero survival. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536271     DOI: 10.1002/pd.139

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  6 in total

1.  A case of triploidy detected by crosstrimester test.

Authors:  Paolo Guanciali-Franchi; Irene Iezzi; Barbara Matarrelli; Elisena Morizio; Giuseppe Calabrese; Giandomenico Palka
Journal:  J Prenat Med       Date:  2012-07

2.  Triploidy in a fetus following amniocentesis referred for maternal serum screening test at second trimester.

Authors:  E Bagherizadeh; M Oveisi; Z Hadipour; A Saremi; Y Shafaghati; F Behjati
Journal:  Indian J Hum Genet       Date:  2010-05

3.  Perinatal Screening for Congenital Malformations and Genetic Disorders: Current Status and Future Directions.

Authors:  Harold N Bass; Jamie Beavers Taylor
Journal:  Perm J       Date:  2002

Review 4.  Non-invasive prenatal screening: A 20-year experience in Italy.

Authors:  Chiara Palka; Paolo Guanciali-Franchi; Elisena Morizio; Melissa Alfonsi; Marco Papponetti; Giulia Sabbatinelli; Giandomenico Palka; Giuseppe Calabrese; Peter Benn
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-18

Review 5.  Non-invasive prenatal screening for fetal triploidy using single nucleotide polymorphism-based testing: Differential diagnosis and clinical management in cases showing an extra haplotype.

Authors:  Valerie Kantor; Russ Jelsema; Wenbo Xu; Wendy DiNonno; Kathryn Young; Zachary Demko; Peter Benn
Journal:  Prenat Diagn       Date:  2022-05-21       Impact factor: 3.242

Review 6.  Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects.

Authors:  Peter Benn
Journal:  J Clin Med       Date:  2014-05-21       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.